Navigation Links
Irene Hegeman Richard, MD, Appointed Senior Medical Advisor to The Michael J. Fox Foundation
Date:11/29/2007

NEW YORK, Nov. 29 /PRNewswire-USNewswire/ -- In keeping with The Michael J. Fox Foundation's mission to accelerate scientific breakthroughs that can transform the lives of people with Parkinson's disease, the Foundation today announced the appointment of Irene Hegeman Richard, MD, to the newly created role of Senior Medical Advisor. This appointment formalizes the role of Dr. Richard, who is associate professor of neurology and psychiatry at the University of Rochester School of Medicine and Dentistry, in helping to inform and develop MJFF's clinical agenda.

Dr. Richard brings experience in running large-scale Parkinson's trials and is familiar with the challenges facing this research area. Formalizing her role as advisor to the Foundation will help ensure that MJFF's increasing involvement in clinical trials, including trial design and regulatory issues, is as efficient and targeted as possible. She will also provide important feedback on pre-clinical experimental design, helping to ensure that all studies funded by MJFF --- not only those requiring the active involvement of patients --- are designed with potential clinical issues in mind.

"Irene's clinical research perspective complements the scientific expertise of Gene Johnson, PhD, MJFF's chief scientific advisor, and her input will be a boon to our research staff and advisors in continually raising the bar on the patient-relevant outcomes we expect from every project we fund," said Katie Hood, interim CEO of The Michael J. Fox Foundation. "Additionally, as a clinician with an active neurology practice, Irene has a deep understanding of the challenges faced every day by people living with PD --- something the Foundation values deeply, since patients are at the center of every activity we undertake."

Dr. Richard has served on the Foundation's SAB since 2006. She also has been a member of the review committee for the Foundation's annual Clinical Discovery Program, which funds high-impact clinical projects in PD, since the program was first launched in 2004, and has played a key role in continually refining its specific criteria for patient-relevant grant selection. Additionally, she has frequently spoken to MJFF friends and supporters at the Foundation's Research Roundtable events across the country.

At the University of Rochester, Dr. Richard provides neurological care for people living with PD and runs a research program focused on the psychiatric aspects of the illness. She is currently leading an NIH-funded multi-center clinical trial evaluating the treatment of depression in PD. She has given lectures and chaired workshops and symposia at national meetings including the American Academy of Neurology and The World Parkinson Congress.

"As a grant reviewer for the Foundation and a member of its Scientific Advisory Board, I've been impressed by The Michael J. Fox Foundation's extraordinary commitment to speeding scientific solutions to the clinic and patients --- a commitment I share," said Dr. Richard. "The Foundation understands that it's never too early in the drug development process to think clinically, and I'm thrilled to take on formal responsibility for working with its staff and advisors to continually improve our ability to do this across the board."

About The Michael J. Fox Foundation

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within this decade through an aggressively funded research agenda. The Foundation has funded over $98 million in research to date, either directly or through partnerships.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Dr. Allen Woolf Appointed Chief Medical Officer For CIGNA Group Insurance
2. William Moore Appointed to IRIDEX Board of Directors
3. Roy Jakobs Appointed Elsevier Managing Director, A&G Sales and Customer Marketing
4. Katie Hood Appointed Interim Chief Executive Officer of Michael J. Fox Foundation
5. Theodore A. Boutacoff Appointed President & CEO of IRIDEX
6. James B. Hawkins Appointed to IRIDEX Board of Directors
7. Bryan R. Rogers Appointed President of Far West Division
8. Catholic Health Association Disappointed by Failure to Override SCHIP Veto
9. Steven M. Safyer, MD, Appointed President and CEO of Montefiore Medical Center
10. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
11. Oral Health a Matter of Life and Death for Seniors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , ... March 23, 2017 , ... ... services to their communities, 16 more public health departments have been awarded national ... bring another 4.5 million people into the expanding network of communities across the ...
(Date:3/23/2017)... ... 23, 2017 , ... The IoT (Internet of Things) is revolutionizing the way ... impact on businesses and individual consumers alike. Laboratories can maximize their profit margin ... anywhere from $4 trillion to $11 trillion dollars by the year 2025. McKinsey expects ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... businesses of the Norwalk and Vermillion areas, celebrates the newest charity campaign ... a nonprofit, community-based substance abuse prevention and peer recovery support organization providing ...
(Date:3/23/2017)... ... 23, 2017 , ... The StayWell Company announced today that ... covers StayWell’s asthma, coronary artery disease, congestive heart failure, chronic obstructive pulmonary disease, ... excellent programs for the delivery and improvement of disease management and that meet ...
(Date:3/23/2017)... ... March 23, 2017 , ... The TouchPoint Solution, home of Buzzies ... stress and anxiety. , “Buzzies change the way we interact with stress and ... , Since its launch date in December 2016, The TouchPoint Solution has sold more ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... , March 23, 2017  Mirabilis Medical, a ... medical technology for non-invasive surgery, announced today CE ... for treatment of uterine fibroids throughout the European ... received approval from the US Food and Drug ... Mirabilis System in the United States.  The Mirabilis ...
(Date:3/24/2017)... , March 24, 2017 ... to develop sutezolid as effective response to infectious disease ... Alliance and the Medicines Patent Pool (MPP) announced a ... antibiotic drug candidate which demonstrated encouraging results in early ... in combination with other TB drugs and follows the ...
(Date:3/23/2017)... 2017 Research and Markets has announced the ... Industry Forecast to 2025" report to their offering. ... The Global Cryostat Market ... the next decade to reach approximately $3.5 billion by 2025. ... all the given segments on global as well as regional levels ...
Breaking Medicine Technology: